# A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Ly

Source: https://onco.cc/trials/nct04442022/  
OnCo record `nct04442022` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Selinexor, Rituximab, Gemcitabine in diffuse large b-cell lymphoma, run by Karyopharm Therapeutics Inc, active and no longer recruiting.

## Summary

A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma is a phase 2/3 interventional study registered as NCT04442022 by Karyopharm Therapeutics Inc, with 501 participants planned, started 2020-09-03 and due to reach its primary completion in 2026-12. Interventions recorded: Selinexor (combination therapy), Selinexor (combination therapy), Selinexor (combination therapy), Placebo matching for Selinexor (combination therapy), Rituximab (combination therapy). Conditions listed: Relapsed/Refractory Diffuse Large B-cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04442022
- Phase: 2/3
- Setting: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (RR DLBCL)
- Sponsor: Karyopharm Therapeutics Inc
- Enrolled: 501

## Sources

- ClinicalTrials.gov NCT04442022: https://clinicaltrials.gov/study/NCT04442022

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Dexamethasone](https://onco.cc/drugs/dexamethasone/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [Rituximab](https://onco.cc/drugs/rituximab/), [Selinexor](https://onco.cc/drugs/selinexor/)
- companies: [Karyopharm Therapeutics](https://onco.cc/companies/karyopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct04442022.json